Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

08/18
2017

Blood Test Finds Cancer Before Symptoms Start

Blood Test Finds Cancer Before First Symptoms Start: From NBC News Researchers say they have taken a big step towards developing a test that can tell people if they have cancer long before the first symptoms show up. The blood test detec…

08/18
2017

Newly Diagnosed with Lung Cancer? Get a Second Opinion

The idea of getting a second opinion after a lung cancer diagnosis may make you feel uncomfortable. But cancer organizations, including the American Society of Clinical Oncology and the Lung Cancer Foundation of America, say second opinions…

08/15
2017

Too Many Drugs in Too Many Trials and Not Enough Patients?

Too Many Drugs,Too Many Trials, Not Enough Patients With the arrival of two revolutionary treatment strategies, immunotherapy and personalized medicine, cancer researchers have found new hope — and a problem that is perhaps unprecedented i…

08/14
2017

Lung cancer diagnosis increases suicide risk by 420%

Lung cancer diagnosis increases suicide risk by 420%, according to a recent study. HemOncToday says: Patients with lung cancer appeared more than four times as likely to commit suicide as individuals in the general population, accordi…

08/14
2017

New Trial for NSCLC Patients with no Previous Immunotherapy Opens

New Trial for NSCLC Patients with no Previous Immunotherapy Opens According to the Thoracic Oncology Translational Research Patient Newsletter, UCLA is happy to announce that the BMS CA209-817 Trial is now open for second-line NSCLC patient…

08/8
2017

Alecensa Gets Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

Alecensa for ALK-Positive Lung Cancer: Priority Review For Treatment from Business Wire Second positive Phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lower…

07/25
2017

Changes to Improve Usability of ClinicalTrials.gov

Improve usability of clinicaltrials.gov: The National Institutes of Health website to search for clinical trials is undergoing a series of changes focused on improving the ability to search, display, and review information about clinical t…

07/14
2017

New CDC Report Shows Deaths from Cancer Higher in Rural America

The CDC's July 7, 2017                       Morbidity and Mortality Weekly Report shows a slower reduction in cancer death rates in rural America comp…

07/6
2017

Full FDA Approval Granted for Anti-Cancer Drug Targeting EGFR Protein Found in Lung Cancer and Mesothelioma

Good news for Mesothelioma patients: FDA approves Tagrisso for lung cancer patients with the EGFR T790M mutation. Learn More…

06/27
2017

FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) announced approval of Tafinlar (dabrafenib) and Mekinist (trametinib) to be delivered in combination for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V60…

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson